• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2021.16064

Pathology of angiogenesis in development and progression of diabetic microangiopathy

[Original research] [Internal diseases]
Svetlana Berstneva; Inessa Dubinina; Oleg Uryasev;

The aim of the study was to investigate the role of Vascular Endothelial Growth Factor (VEGF) in the development and progression of diabetic retinopathy (DR) and diabetic nephropathy (DN) in patients with diabetes mellitus (DM). In 73 diabetic patients with the presence (42 patients) or absence of DR (31 patients), VEGF-A and albuminuria parameters were studied, and daily blood pressure monitoring was performed. In patients with DR, an increase in the content of creatinine, VEGF-Ain the blood, indicators of albuminuria, a decrease in GFR, and a daily index of diastolic blood pressure were revealed. The maximum VEGF-A values were found in patients with proliferative and complicated proliferative DR. Serum VEGF-A concentration increased in the early stages of DN. A positive correlation was established between VEGF-A and albuminuria values.

Download

References:
1. Behl T., Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF)in diabetic retinopathy. Pharmacol. Res. 2015;99:137-148.
https://doi.org/10.1016/j.phrs.2015.05.013
2. Neroev V. V., Zaytseva O. V., Balatskaya N. V.,Kurchaeva Z. V. Local and systemic VEGF-А production in complicated proliferative diabetic retinopathy. Medicinskaya Immunologiya. – Medical Immunology.2016;18(4):357-364. (In Russ.)].
https://doi.org/10.15789/1563-0625-2016-4-357-364
3. Konenkov V. I., Klimontov V. V.Vasculogenesis and angiogenesis in diabetes mellitus: novel pathogenetic concepts for treatment of vascular complications. Saharnyj Diabet. – Diabetes mellitus.2012;(4):17-27. (In Russ.)].
4. Hanefeld M., Appelt D., Engelmann K., Sandner D.,Bornstein S. R. [et al.]. Serum and plasma levels ofvascular endothelial growth factors in relation to quality ofglucose control, biomarkers of inflammation, and diabetic nephropathy. Horm. Metab. Res. 2016;48(8):529-534.
https://doi.org/10.1055/s-0042-106295
5. Dubinina I. I., Uryasev O. M., Berstneva S. V., Nikiforov A. A. Hypertension and endothelialdysfunction in comorbid pathology: diabetes mellitus andprimary hypothyroidism. Rossijskij mediko-biologicheskijvestnik imeni akademika I. P. Pavlova. – I. P. PavlovRussian Medical Biological Herald. 2016;24(4):42-55. (InRuss.).
https://doi.org/10.23888/PAVLOVJ2016442-55
6. Shestakova M. V., Severina A. S., Dedov I. I. Oslozhneniya saharnogo diabeta. M.: «MIA», 2017. (In Russ.).
7. Amle D., Mir R., Khaneja A., Agarwal S., Ahlawat R. [etal.]. Association of 18bp insertion/deletion polymorphism, at −2549 position of VEGF gene, with diabetic nephropathy in type 2 diabetes mellitus patients of North Indian population. J. Diabetes Metabol. Disorders. 2015;14-19.
https://doi.org/10.1186/s40200-015-0144-3
8. Veron D., Bertuccio C. A., Marlier A., Reidy K., Garcia A. M., Jimenez J. Podocyte vascular endothelial growthfactor (Vegf164) overexpression causes severe nodularglomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia. 2011;54(5):1227-1241.
https://doi.org/10.1007/s00125-010-2034-z
9. Brosius F. C., Coward R. J. Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv.Chronic Kidney Dis. 2014;21(3):304-310.
https://doi.org/10.1053/j.ackd.2014.03.011
10. Sim S. Y., Ghulakhszian A., Minocha A., Ramcharan D.,Nokhostin S. [et al.]. Factors influencing response to Aflibercept in diabetic macular oedema patients in a diverse North West London population: a real-world study. Clin.Ophthalmol. 2021;20(15):2089-2097.
https://doi.org/10.2147/OPTH.S314614
11. Lai T. T., Yang C. M., Yang C. H., Ho T. C., Hsieh Y. T. Treatment outcomes and predicting factors for diabetic macularedema treated with Ranibizumab – One-year real-life results in Taiwan. J. Formos. Med. Assoc. 2019;118(1):194-202.
https://doi.org/10.1016/j.jfma.2018.03.009
12. Cheng Y., Yuan L., Zhao M. W., Qian T. Real-world outcomes of two-year Conbercept therapy for diabetic macular edema. Int. J. Ophthalmol. 2021;14(3):416-422.
https://doi.org/10.18240/ijo.2021.03.14
13. Sivaskandarajah G. A., Jeansson M., Maezawa Y.,Eremina V., Baelde H. J., Quaggin S. E. VEGF-A protects the glomerular microvasculature in diabetes. Diabetes.2012;61(11):2958-2966.
https://doi.org/10.2337/db11-1655
14. Tao Q. R., Chu Y. M., Wei L., Tu C., Han Y. Y. Antiangiogenic therapy in diabetic nephropathy: a double‑edgedsword (Review). Mol. Med. Rep. 2021;23(4):260.
https://doi.org/10.3892/mmr.2021.11899
15. Tanabe K., Maeshima Y., Sato Y., Wada J. Antiangiogenic therapy for diabetic nephropathy. Biomed. Res. Int.2017;2017:5724069.
https://doi.org/10.1155/2017/5724069
16. Hernandez-Arteaga K., Soto-Abraham V., Perez-Navarro M., de Leon-Garza B., Rodríguez-Matías A. [et al.]. Thrombotic microangiopathy in patients with diabetic nephropathy is associated with low VEGF expression and end-stage renal disease. Clin. Nephrol. 2018;89(6):429-437.
https://doi.org/10.5414/CN109240
17. O’Neill R. A., Gallagher P., Douglas T., Little J. A., Maxwell A. P. [et al.]. Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol. 2019;20(1):478.
https://doi.org/10.1186/s12882-019-1650-1
18. Zhang A., Fang H., Chen J., He L., Chen Y. Role of VEGF-Aand LRG1 in abnormal angiogenesis associated with diabetic nephropathy. Front. Physiol. 2020;31(11):1064.
https://doi.org/10.3389/fphys.2020.01064
19. Chumakova O. S.,Tipteva T. A., Reznichenko N. E., Zateyshicov D. A. Arterial hypertension complicated by myocardial hypertrophy and heart failure is associated with lower serum levels of vascular endothelium growth factor (VEGF-A165).Kardiologiya. – Сardiology. 2015;10:14-18. (In Russ.).
https://doi.org/10.18565/cardio.2015.10.14-18
20. Zangelova T. E., Gladkikh N. N., Yagoda A. V. Рrognostic value of vascular endothelial growth factor in patientswith mitral valve prolapse and connective tissue dysplasia. Medicinskii vestnik Severnogo Kavkaza. – MedicalNews of North Caucasus. 2017;12(4):361-365. (In Russ.).
https://doi.org/10.14300/mnnc.2017.12101
21. Deev R. V., Mzhavanadze N. D.Parameters of macro- and microhemodynamics in patientswith atherosclerotic chronic lower limb ischemia aftergene therapy with pVEGF165. Nauka molodykh (Eruditio Juvenium). – Science of the young (Eruditio Juvenium).2014;1:68-73. (In Russ.).

Keywords: diabetic retinopathy, diabetic nephropathy, vascular endothelial growth factor, pathologic angiogenesis